编辑推荐：肝癌免疫治疗面临肿瘤微环境(TME)免疫抑制的挑战，上海交通大学医学院团队发现CCR8 + Tregs在肝癌组织中显著富集，自主研发的CCR8拮抗剂IPG0521m通过将Tregs从高免疫抑制表型转化为低免疫抑制表型，显著增强CD8 + T细胞和NK细胞抗肿瘤活性，为肝癌免疫 ...

Details of the poster presentations are as follows: Poster Title: Comprehensive Characterization of DT-7012, a Differentiated CCR8-Depleting Antibody for the Treatment of Solid Tumors Session ...

Domain Therapeutics ("Domain" or "the Company"), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces that it will be presenting new ...

Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology ...

Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial ...